Moderna and Pfizer are Clear Winners vs Johnson & Johnson

The Center for Disease Control (CDC) has recommended a preference of Moderna and Pfizer Covid-19 booster shots over Johnson & Johnson variable, as Johnson & Johnson continues to struggle with the blood clotting issue, which has since seen nine deaths and several dozen cases of other complications with regards to the use of the Johnson & Johnson vaccine.

Out of the nine deaths associated with the Johnson & Johnson vaccine, 7 of the patients did have underlying health concerns. The other two aren’t clear. Dozens fell sick, and they are also under investigation.

Johnson & Johnson’s vaccine appeal had to do with it being a single dose vaccine with no special storage requirement. However, it is certainly less appealing due to its lower effectiveness and higher risk in terms of the blood clot issue. Only about 17 million have administered the Johnson & Johnson dosage, whereas the 470 million of the Pfizer and Moderna have been administered.

As Johnson & Johnson did advertise its easy use as one of its main advantages, this will make vaccinating homeless or prisoners more difficult, as their positions are more difficult to reach, and transportation of the other alternatives are harder.

Because of this weakness in Johnson & Johnson vaccine, the CDC, which tends to hold back on having a preferential recommendation, has done so in this case.

Johnson & Johnson continues to remain firm on the quality of their vaccines, but it may become a very special-use vaccine rather than a nationwide one.